Regulation of angiogenesis by hypoxia-inducible factor 1

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 1, 2006, Pages 15-26

  Hirota, Kiichi ^a   Semenza, Gregg L ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arteriogenesis; Cancer; HIF 1; Ischemia; Prolyl hydroxylase; Vascular endothelial growth factor

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 METHOXYESTRADIOL; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DIMETHYLOXALYLGLYCINE; DNA TOPOISOMERASE INHIBITOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GLYCINE DERIVATIVE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; OLIGONUCLEOTIDE; OXYGEN; OXYGENASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PR 39; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN INHIBITOR; PX 478; RAPAMYCIN; STROMAL CELL DERIVED FACTOR 1; TOPOTECAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CANCER CELL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ENDOTHELIUM CELL; GENE CONTROL; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SUPPLY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; TRANSCRIPTION, GENETIC;

EID: 33745138232     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.12.003     Document Type: Review

References (178)

1. Hochachka P.W., Buck L.T., Doll C.J., and Land S.C. Unifying theory of hypoxia tolerance: molecular/metabolic defence and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93 (1996) 9493-9498
2. Hochachka P.W., Gunga H.C., and Kirsh K. Our ancestral physiological phenotype: an adaptation for hypoxia tolerance and for endurance performance?. Proc Natl Acad Sci USA 95 (1998) 1915-1920
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
4. Giaccia A.J., Simon M.C., and Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 18 (2004) 2183-2194
5. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123 (2005) 991-999
6. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
7. Stohrer M., Boucher Y., Stangassinger M., and Jain R.K. Oncotic pressure in solid tumors is elevated. Cancer Res 60 (2000) 4215-4255
8. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 3 (1992) 65-71
9. Semenza G.L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 19 (2000) 59-65
10. Richard D.E., Berra E., and Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 266 (1999) 718-722
11. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12 (1992) 5447-5454
12. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270 (1995) 1230-1237
13. 2 tension. Proc Natl Acad Sci USA 92 (1995) 5510-5514
14. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271 (1996) 17771-17778
15. Tian H., McKnight S.L., and Russel D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11 (1997) 72-82
16. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third α-class hypoxia-inducible factor subunit, HIF3α. Gene Expression 7 (1998) 205-213
17. Wiesener M.S., Turley H., Allen W.E., et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 92 (1998) 2260-2268
18. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23 (2003) 9361-9374
19. Raval R.R., Lau K.W., Tran M.G., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (2005) 5675-5686
20. Hara S., Hamada J., Kobayashi C., Kondo Y., and Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3α in human kidney: suppression of HIF-mediated gene expression by HIF-3α. Biochem Biophys Res Commun 287 (2001) 808-813
21. Makino Y., Cao R., Svensson K., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414 (2001) 550-554
22. Manalo D.J., Rowan A., Lavoie T., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
23. 2 tension. Am J Physiol 271 (1996) C1172-C1180
24. Salceda S., and Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272 (1997) 22642-22647
25. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
26. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95 (1998) 17987-17992
27. Ruas J.L., Poellinger L., and Pereira T. Role of CBP in regulating HIF-1-mediated activation of transcription. J Cell Sci 118 (2005) 301-311
28. Maxwell P.H. HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle 3 (2004) 156-159
29. Kaelin W.G. Proline hydroxylation and gene expression. Annu Rev Biochem 74 (2005) 115-128
30. McNeill L.A., Hewitson K.S., Gleadle J.M., et al. The use of dioxygen by HIF prolyl hydroxylase (PHD1). Bioorg Med Chem Lett 12 (2002) 1547-1550
31. Epstein A.C., Gleadle J.M., McNeill L.A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
32. Bruick R., and McKnight S. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
33. Baek J.H., Mahon P.C., Oh J., et al. OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol Cell 17 (2005) 503-512
34. Elkins J.M., Hewitson K.S., McNeill L.A., et al. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1α. J Biol Chem 278 (2003) 1802-1806
35. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16 (2002) 1466-1471
36. Lee C., Kim S.J., Jeong D.G., Lee S.M., and Ryu S.E. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J Biol Chem 278 (2003) 7558-7563
37. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15 (2001) 2675-2686
38. Schofield C.J., and Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 9 (1999) 722-731
39. Hirsila M., Koivunen P., Gunzler V., Kivirikko K.I., and Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278 (2003) 30772-30780
40. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., and Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279 (2004) 9899-9904
41. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
42. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277 (2002) 38205-38211
43. Richard D.E., Berra E., and Pouyssegur J. Non-hypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem 275 (2000) 26765-26771
44. Page E.L., Robitaille G.A., Pouyssegur J., and Richard D.E. Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J Biol Chem 277 (2002) 48403-48409
45. Hirota K., Fukuda R., Takabuchi S., et al. Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. J Biol Chem 279 (2004) 41521-41528
46. Kasuno K., Takabuchi S., Fukuda K., et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling. J Biol Chem 279 (2004) 2550-2558
47. Metzen E., Zhou J., Jelkmann W., Fandrey J., and Brune B. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Cell Biol 14 (2003) 3470-3481
48. Hagen T., Taylor C.T., Lam F., and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF-1α. Science 302 (2003) 1975-1978
49. Callapina M., Zhou J., Schnitzer S., et al. Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1α accumulation-implications for prolyl hydroxylase activity and iron. Exp Cell Res 306 (2005) 274-284
50. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
51. Talks K.L., Turley H., Gatter K.C., et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157 (2000) 411-421
52. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
53. Seagroves T.N., Ryan H.E., Lu H., et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 21 (2001) 3436-3444
54. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12 (1998) 149-162
55. Warburg O. The oxygen-transferring ferment of respiration: Nobel lecture, December 10, from Nobel lectures, physiology or medicine, 1922-1941 (1965), Elsevier Publishing Company, Amsterdam
56. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
57. Conway E.M., Collen D., and Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 49 (2001) 507-521
58. Papetti M., and Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol 282 (2002) C947-C970
59. Carmeliet P., Dor Y., Herbert J., et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394 (1998) 485-490
60. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C., and Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386 (1997) 403-407
61. Kotch L.E., Iyer N.V., Laughner E., and Semenza G.L. Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Develop Biol 209 (1999) 254-267
62. Tomita S., Ueno M., Sakamoto M., et al. Defective brain development in mice lacking the HIF-1α gene in neural cells. Mol Cell Biol 23 (2003) 6739-6749
63. Tang N., Wang L., Esko J., et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
64. Kelly B.D., Hackett S.F., Hirota K., et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93 (2003) 1074-1081
65. Peng J., Zhang L., Drysdale L., and Fong G.H. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodelling. Proc Natl Acad Sci USA 97 (2000) 8386-8391
66. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12 (1998) 3320-3324
67. Compernolle V., Brusselmans K., Acker T., et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8 (2002) 702-710
68. Rajagopalan S., Mohler E., Lederman R., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
69. Lederman R.J., Mendelsohn F.O., Anderson R.D., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359 (2000) 2953-2958
70. Sutter C.H., Laughner E., and Semenza G.L. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 97 (2000) 4748-4753
71. Elson D.A., Thurston G., Huang L.E., et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev 15 (2001) 2520-2532
72. Vincent K.A., Feron O., and Kelly R.A. Harnessing the response to tissue hypoxia: HIF-1α and therapeutic angiogenesis. Trends Cardiovasc Med 12 (2002) 362-367
73. Shyu K., Wang M., Wang B., et al. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 54 (2002) 576-583
74. Patel T.H., Kimura H., Weiss C.R., Semenza G.L., and Hofmann L.V. Constitutively active HIF-1α improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 68 (2005) 144-154
75. Li J., Post M., Volk R., et al. PR39, a peptide regulator of angiogenesis. Nat Med 61 (2000) 49-55
76. Milkiewicz M, Pugh CW, Egginton S. Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol 2004;560:21-6.
77. Resar J.R., Roguin A., Voner J., et al. Hypoxia-inducible factor 1α polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 128 (2005) 787-791
78. Stoeltzing O., McCarty M.F., Wey J.S., et al. Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 96 (2004) 946-956
79. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14 (2000) 34-44
80. Rapisarda A., Uranchimeg B., Scudiero D.A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62 (2002) 4316-4324
81. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., and Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64 (2004) 1475-1482
82. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
83. Macpherson G.R., and Figg W.D. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biol Ther 3 (2004) 503-504
84. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., and Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther 3 (2004) 233-244
85. Kung A.L., Zabludoff S.D., France D.S., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-34
86. Isaacs J.S., Xu W., and Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3 (2003) 213-217
87. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
88. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
89. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF-1α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
90. Moeller B.J., Dreher M.R., Rabbani Z.N., et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
91. Krishnamurthy P., Ross D.D., Nakanishi T., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279 (2004) 24218-24225
92. 1B-adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle. Proc Natl Acad Sci USA 94 (1997) 9487-9492
93. Cormier-Regard S., Nguyen S.V., and Claycomb W.C. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 273 (1998) 17787-17792
94. Ryan H.E., Lo J., and Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998) 3005-3015
95. Chun Y.S., Hyun J.Y., Kwak Y.G., et al. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 370 (2003) 149-157
96. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.H. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene 19 (2000) 6297-6305
97. 2 integrin gene expression. Proc Natl Acad Sci USA 101 (2004) 10440-10445
98. Mukhopadhyay C.K., Mazumder B., and Fox P.L. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 275 (2000) 21048-21054
99. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
100. Higgins D.F., Biju M.P., Akai Y., Wutz A., Johnson R.S., and Haase V.H. Hypoxic induction of Ctgf is directly mediated by HIF-1. Am J Physiol 287 (2004) F1223-F1232
101. Fradette C., and du Souich P. Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia. Br J Pharmacol 140 (2003) 1146-1154
102. Zagzag D., Krishnamachary B., Yee H., et al. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear-cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65 (2005) 6178-6188
103. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 425 (2003) 307-311
104. Schioppa T., Uranchimeg B., Saccani A., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198 (2003) 1391-1402
105. Miyazaki K., Kawamoto T., Tanimoto K., Nishiyama M., Honda H., and Kato Y. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J Biol Chem 277 (2002) 47014-47021
106. Synnestvedt K., Furuta G.T., Comerford K.M., et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110 (2002) 993-1002
107. LeCouter J., Kowalski J., Foster J., et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412 (2001) 877-884
108. Sanchez-Elsner T., Botella L.M., Velasco B., Langa C., and Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 277 (2002) 43799-43808
109. Hu J., Discher D.J., Bishopric N.H., and Webster K.A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 245 (1998) 894-899
110. Semenza G.L., Jiang B.H., Leung S.W., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271 (1996) 32529-32537
111. Coulet F., Nadaud S., Agrapart M., and Soubrier F. Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J Biol Chem 278 (2003) 46230-46240
112. Oikawa M., Abe M., Kurosawa H., Hida W., Shirato K., and Sato Y. Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289 (2001) 39-43
113. Wood S.M., Wiesener M.S., Yeates K.M., et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 α-subunit (HIF-1α). Characterization of HIF-1α-dependent and -independent hypoxia-inducible gene expression. J Biol Chem 273 (1998) 8360-8368
114. Graven K.K., Yu Q., Pan D., Roncarati J.S., and Farber H.W. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim Biophys Acta 1447 (1999) 208-218
115. Lu S., Gu X., Hoestje S., and Epner D.E. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim Biophys Acta 1574 (2002) 152-156
116. Paris S., Denis H., Delaive E., et al. Up-regulation of 94-kDa glucose-regulated protein by hypoxia-inducible factor-1 in human endothelial cells in response to hypoxia. FEBS Lett 579 (2005) 105-114
117. Lee P.J., Jiang B.H., Chin B.Y., et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272 (1997) 5375-5381
118. Pescador N., Cuevas Y., Naranjo S., et al. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J 390 (2005) 189-197
119. Metzen E., Stiehl D.P., Doege K., Marxsen J.H., Hellwig-Burgel T., and Jelkmann W. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 387 (2005) 711-717
120. Lee M.J., Kim J.Y., Suk K., and Park J.H. Identification of the hypoxia-inducible factor 1α-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathway. Mol Cell Biol 24 (2004) 3918-3927
121. Lofstedt T., Jogi A., Sigvardsson M., et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 279 (2004) 39223-39231
122. Furuta G.T., Turner J.R., Taylor C.T., et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 193 (2001) 1027-1034
123. Lee S.Y., Madan A., Furuta G.T., Colgan S.P., and Sibley E. Lactase gene transcription is activated in response to hypoxia in intestinal epithelial cells. Mol Genet Metab 75 (2002) 65-69
124. Grosfeld A., Andre J., Hauguel-De Mouzon S., Berra E., Pouyssegur J., and Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 277 (2002) 42953-42957
125. Petrella B.L., Lohi J., and Brinckerhoff C.E. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel-Lindau renal cell carcinoma. Oncogene 24 (2005) 1043-1052
126. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62 (2002) 3387-3394
127. Piret J.P., Minet E., Cosse J.P., et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 280 (2005) 9336-9344
128. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182 (1995) 1683-1693
129. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97 (2000) 9082-9087
130. Choi J., Park S., Kang G., Liu J., and Youn H. Nur77 activated by hypoxia-inducible factor-1α overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Cancer Res 64 (2004) 35-39
131. Bhattacharya S., Michels C.L., Leung M.K., Arany Z.P., Kung A.L., and Livingston D.M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13 (1999) 64-75
132. Firth J.D., Ebert B.L., Pugh C.W., and Ratcliffe P.J. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 91 (1994) 6496-6500
133. Minchenko A., Leshchinsky I., Opentanova I., et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277 (2002) 6183-6187
134. Fukasawa M., Tsuchiya T., Takayama E., et al. Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. J Biochem (Tokyo) 136 (2004) 273-277
135. Minchenko O., Opentanova I., and Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett 554 (2003) 264-270
136. Kietzmann T., Roth U., and Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94 (1999) 4177-4185
137. Takahashi Y., Takahashi S., Shiga Y., Yoshimi T., and Miura T. Hypoxic induction of prolyl 4-hydroxylase α(I) in cultured cells. J Biol Chem 275 (2000) 14139-14146
138. Miki N., Ikuta M., and Matsui T. Hypoxia-induced activation of the retinoic acid receptor-related orphan receptor α4 gene by an interaction between hypoxia-inducible factor-1 and Sp1. J Biol Chem 279 (2004) 15025-15031
139. Chauvet C., Bois-Joyeux B., Berra E., Pouyssegur J., and Danan J.L. The gene encoding human retinoic acid-receptor-related orphan receptor α is a target for hypoxia-inducible factor 1. Biochem J 384 (2004) 79-85
140. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
141. Nishi H., Nakada T., Kyo S., Inoue M., Shay J.W., and Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 24 (2004) 6076-6083
142. Rolfs A., Kvietikova I., Gassmann M., and Wenger R.H. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272 (1997) 20055-20062
143. Lok C.N., and Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274 (1999) 24147-24152
144. Tacchini L., Fusar Poli D., Bernelli-Zazzera A., and Cairo G. Transferrin receptor gene expression and transferrin-bound iron uptake are increased during postischemic rat liver reperfusion. Hepatology 36 (2002) 103-111
145. Caniggia I., Mostachfi H., Winter J., et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 105 (2000) 577-587
146. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272 (1997) 23659-23667
147. Hansen W.J., Ohh M., Moslehi J., Kondo K., Kaelin W.G., and Welch W.J. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol 22 (2002) 1947-1960
148. Morris M.R., Maina E., Morgan N.V., et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumor suppressor genes in renal cell carcinoma. J Clin Pathol 57 (2004) 706-711
149. Pollard P.J., Briere J.J., Alam N.A., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF-1α in tumors which result from germline FH and SDH mutations. Hum Mol Genet 14 (2005) 2231-2239
150. Selak M.A., Armour S.M., MacKenzie E.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
151. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
152. Liu M.Y., Poellinger L., and Walker C.L. Up-regulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 63 (2003) 2675-2680
153. ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J Biol Chem 276 (2001) 28421-28429
154. Chan D.A., Sutphin P.D., Denko N.C., and Giaccia A.J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 277 (2002) 40112-40117
155. Karni R., Dor Y., Keshet E., Meyuhas O., and Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1α expression under normoxia. J Biol Chem 277 (2002) 42919-42925
156. Korkolopoulou P., Patsouris E., Konstantinidou A., et al. Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas: associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 3 (2004) 267-278
157. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., et al. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumor recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95 (2005) 425-431
158. Theodoropoulos V.E., Lazaris A., Sofras F., et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46 (2004) 200-208
159. Bos R., Zhong H., Hanrahan C.F., et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93 (2001) 309-314
160. Giatromanolaki A., Koukourakis M.I., Simopoulos C., et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia-inducible factor-1α dependent. Clin Cancer Res 10 (2004) 7972-7977
161. Schindl M., Schoppmann S.F., Samonigg H., et al. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8 (2002) 1831-1837
162. Bos R., van der Groep P., Greijer A.E., et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
163. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60 (2000) 4693-4696
164. Burri P., Djonov V., Aebersold D.M., et al. Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 494-501
165. Bachtiary B., Schindl M., Potter R., et al. Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9 (2003) 2234-2240
166. Kuwai T., Kitadai Y., Tanaka S., et al. Expression of hypoxia-inducible factor-1α is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 105 (2003) 176-181
167. Kimura S., Kitadai Y., Tanaka S., et al. Expression of hypoxia-inducible factor (HIF)-1α is associated with vascular endothelial growth factor expression and tumor angiogenesis in human esophageal squamous cell carcinoma. Eur J Cancer 40 (2004) 1904-1912
168. Matsuyama T., Nakanishi K., Hayashi T., et al. Expression of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma. Cancer Sci 96 (2005) 176-182
169. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., and Koukourakis M.I. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (2002) 1055-1063
170. Takahashi R., Tanaka S., Hiyama T., et al. Hypoxia-inducible factor-1α expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 10 (2003) 797-802
171. Giatromanolaki A., Koukourakis M., Sivridis E., et al. Relation of hypoxia-inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 85 (2001) 881-890
172. Giatromanolaki A., Sivridis E., and Kouskoukis C. Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13 (2003) 493-501
173. Birner P., Gatterbauer B., Oberhuber G., et al. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92 (2001) 165-171
174. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61 (2001) 2911-2961
175. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
176. Kitada T., Seki S., Sakaguchi H., Sawada T., Hirakawa K., and Wakasa K. Clinicopathological significance of hypoxia-inducible factor-1α expression in human pancreatic carcinoma. Histopathology 43 (2003) 550-555
177. Shibaji T., Nagao M., Ikeda N., et al. Prognostic significance of HIF-1α overexpression in human pancreatic cancer. Anticancer Res 23 (2003) 4721-4727
178. Karth J., Ferrer F.A., Perlman E., et al. Coexpression of hypoxia-inducible factor 1α and vascular endothelial growth factor in Wilms' tumor. J Pediatr Surg 35 (2000) 1749-1753